# **Critical Care COVID-19 Management Protocol**

(updated 6-17-2020)

# **Prophylaxis**

While there is very limited data (and none specific for COVID-19), the following "cocktail" may have a role in the prevention/mitigation of COVID-19 disease.

- Vitamin C 500 mg BID and Quercetin 250-500 mg BID
- Zinc 75-100 mg/day
- Melatonin (slow release): Begin with 0.3mg and increase as tolerated to 2 mg at night
- Vitamin D3 1000-4000 u/day
- Optional: Famotidine 20-40mg/day

## Mildly Symptomatic patients (at home):

- Vitamin C 500mg BID and Quercetin 250-500 mg BID
- Zinc 75-100 mg/day
- Melatonin 6-12 mg at night (the optimal dose is unknown)
- Vitamin D3 2000-4000 u/day
- Optional: Ivermectin 150-200ug/kg (single dose)
- Optional: ASA 81/325mg/day
- Optional: Famotidine 20-40mg/day

In symptomatic patients, monitoring with home pulse oximetry is recommended. Ambulatory desaturation below 94% should prompt hospital admission

# Mildly Symptomatic patients (on floor):

- Vitamin C 500 mg PO q 6 hourly and Quercetin 250-500 mg BID (if available)
- Zinc 75-100 mg/day
- Melatonin 6-12 mg at night (the optimal dose is unknown)
- Vitamin D3 2000-4000 u/day
- Enoxaparin 60 mg daily
- Famotidine 40mg daily (20mg in renal impairment)
- Methylprednisolone 40 mg q 12 hourly; increase to 80 mg q 12 if poor response
- Optional: Remdesivir 200mg D1 then 100mg daily for 9 days.

# General schema for respiratory support in patients with COVID-19

#### TRY TO AVOID INTUBATION IF POSSIBLE

#### **Low-Flow Nasal Cannula**

Typically set at 1-6 Liters/Min

#### **High Flow Nasal Cannula**

- Accept permissive hypoxemia (O<sub>2</sub> Saturation > 86%)
- Titrate FiO<sub>2</sub> based on patient's saturation
- Accept flow rates of 60 to 80 L/min
- Trial of inhaled Flolan (epoprostenol)
- Attempt proning (cooperative proning)

#### **Invasive Mechanical Ventilation**

- Target tidal volumes of ~6 cc/kg
- Lowest driving pressure and PEEP
- Sedation to avoid self-extubation
- Trial of inhaled Flolan

## **Prone Positioning**

- Exact indication for prone ventilation is unclear
- Consider in patients with PaO<sub>2</sub>/FiO<sub>2</sub> ratio < 150

#### **VV-ECMO**

eteriora

- Indications remain unclear
- Early discussion with ECMO center or team may be advisable
- Optional: Ivermectin 150-200 ug/kg (single dose)
- N/C 2L /min if required (max 4 L/min; consider early t/f to ICU for escalation of care).
- T/f EARLY to the ICU for increasing respiratory signs/symptoms and arterial desaturations.

continued on next page



# Critical Care COVID-19 Management Protocol

(updated 6-17-2020)

# Respiratory symptoms (SOB; hypoxia- requiring N/C $\geq$ 4 L min: admit to ICU):

### **Essential Treatment (dampening the STORM)**

- 1. Methylprednisolone 80 mg loading dose then 40 mg q 12 hourly for at least 7 days and until transferred out of ICU. In patients with poor response, increase to 80 mg q 12 hourly.
- 2. Ascorbic acid (Vitamin C) 3g IV q 6 hourly for at least 7 days and/or until transferred out of ICU. Note caution with POC glucose testing.
- 3. Full anticoagulation: Unless contraindicated we suggest FULL anticoagulation (on admission to the ICU) with enoxaparin, i.e 1 mg kg s/c q 12 hourly (dose adjust with Cr Cl < 30mls/min). Heparin is suggested with CrCl < 15 ml/min.

Note: Early termination of ascorbic acid and corticosteroids will likely result in a rebound effect.

### **Additional Treatment Components (the Full Monty)**

- 4. Melatonin 6-12 mg at night (the optimal dose is unknown).
- 5. Famotidine 40mg daily (20mg in renal impairment)
- 6. Vitamin D 2000-4000 u/day
- 7. Thiamine 200mg IV q 12 hourly
- 8. Simvastatin 80 mg/day (caution drug-drug interactions) or Atorvastatin 80 mg/day
- 9. Magnesium: 2 g stat IV. Keep Mg between 2.0 and 2.4 mmol/l. Prevent hypomagnesemia (which increases the cytokine storm and prolongs Qtc).
- 10. Optional: Azithromycin 500 mg day 1 then 250 mg for 4 days
- 11. Optional: Remdesivir, 200 mg IV loading dose D1, followed by 100mg day IV for 9 days
- 12. Broad-spectrum antibiotics if superadded bacterial pneumonia is suspected based on procalcitonin levels and resp. culture (no bronchoscopy).
- 13. Maintain EUVOLEMIA
- 14. Early norepinephrine for hypotension.

15. Escalation of respiratory support; See General Schema for Respiratory Support in Patients with COVID-19.

### **Salvage Treatments**

- Plasma exchange. Should be considered in patients with progressive oxygenation failure despite corticosteroid therapy. Patients may require up to 5 exchanges.
- High dose corticosteroids; 120 mg methylprednisolone q 6-8 hourly
- Siltuximab and Tocilizumab (IL-6 inhibitors)
- Convalescent serum; the role and timing of convalescent serum are uncertain.

#### Treatment of Macrophage Activation Syndrome (MAS)

- A sub-group of patients will develop MAS. A ferritin > 4400 ng/ml is considered diagnostic of MAS. Other diagnostic features include increasing AST/ALT and increasing CRP.
- Methylprednisolone 120 mg q 6-8 hourly for at least 3 days, then wean according to Ferritin, CRP, AST/ALT. Ferritin should decrease by at least 15% before weaning corticosteroids.

# **Monitoring:**

- On admission: PCT, CRP, IL-6, BNP, Troponins, Ferritin, Neutrophil-Lymphocyte ratio, D-dimer and Mg.
- Daily: CRP, Ferritin, D-Dimer and PCT. CRP and Ferritin track disease severity closely (although ferritin tends to lag behind CRP).
- Thromboelastogram (TEG) in patients with high D-dimer and repeated as indicated.
- In patients receiving IV vitamin C, the Accu-Chek™ POC glucose monitor will result in spuriously high blood glucose values. Therefore, a laboratory glucose is recommended to confirm the blood glucose levels

# Post ICU management

- a. Enoxaparin 40-60 mg s/c daily
- b. Methylprednisone 40 mg day, then wean slowly
- c. Vitamin C 500 mg PO BID
- d. Melatonin 3-6 mg at night

